We are live on ! Find out more
FPRX

Five Prime Therapeutics, Inc.
FPRX

Delisted

FPRX was delisted on the 15th of April, 2021.

94 hedge funds and large institutions have $122M invested in Five Prime Therapeutics, Inc. in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 34 increasing their positions, 37 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more capital invested

Capital invested by funds: $105M → $122M (+$17.5M)

8% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 37

9% less funds holding

Funds holding: 10394 (-9)

50% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 18

75% less call options, than puts

Call options by funds: $4K | Put options by funds: $16K

Holders
94
Holders Change
-9
Holders Change %
-8.74%
% of All Funds
1.85%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
34
Reduced
37
Closed
18
Calls
$4K
Puts
$16K
Net Calls
-$12K
Net Calls Change
+$488K
Name Holding Trade Value Shares
Change
Change in
Stake
BI
1
BVF Inc
California
$35.7M +$15.9M +4,017,833 +107%
BlackRock
2
BlackRock
New York
$11.6M -$1.67M -420,484 -14%
Renaissance Technologies
3
Renaissance Technologies
New York
$8.09M +$1.69M +427,080 +32%
Dimensional Fund Advisors
4
Dimensional Fund Advisors
Texas
$7.8M -$106K -26,697 -2%
Vanguard Group
5
Vanguard Group
Pennsylvania
$7.32M -$103K -26,107 -2%
Wellington Management Group
6
Wellington Management Group
Massachusetts
$5.75M -$4.62M -1,167,151 -48%
State Street
7
State Street
Massachusetts
$2.88M -$146K -36,804 -6%
Man Group
8
Man Group
United Kingdom
$2.51M -$3.13M -789,261 -59%
JP Morgan Chase
9
JP Morgan Chase
New York
$2.43M +$489K +123,507 +30%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$2.37M +$199K +50,227 +11%
Two Sigma Investments
11
Two Sigma Investments
New York
$2.17M +$1.16M +294,034 +164%
AQR Capital Management
12
AQR Capital Management
Connecticut
$2.06M +$1.24M +311,832 +227%
EAM
13
Erste Asset Management
Austria
$1.94M +$317K +80,000 +22%
RSCM
14
Rock Springs Capital Management
Maryland
$1.84M -$1.49M -375,000 -48%
Northern Trust
15
Northern Trust
Illinois
$1.81M -$121K -30,652 -7%
Two Sigma Advisers
16
Two Sigma Advisers
New York
$1.67M +$645K +162,800 +81%
Jacobs Levy Equity Management
17
Jacobs Levy Equity Management
New Jersey
$1.66M +$951K +240,056 +198%
Hudson Bay Capital Management
18
Hudson Bay Capital Management
Connecticut
$1.65M -$297K -75,000 -17%
OAM
19
Oxford Asset Management
United Kingdom
$1.35M +$4.65K +1,173 +0.4%
D.E. Shaw & Co
20
D.E. Shaw & Co
New York
$1.31M +$370K +93,402 +48%
Assenagon Asset Management
21
Assenagon Asset Management
Luxembourg
$1.27M -$839K -211,726 -43%
PIM
22
Platinum Investment Management
Australia
$1.15M +$238K +59,979 +31%
Acadian Asset Management
23
Acadian Asset Management
Massachusetts
$1.15M +$373K +94,242 +60%
Adage Capital Partners
24
Adage Capital Partners
Massachusetts
$1.15M -$3.96M -1,000,000 -80%
Charles Schwab
25
Charles Schwab
California
$973K -$23.7K -5,992 -3%

FPRX Hedge Fund Activity: Q4 2019 in Review

94 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q4 2019, worth a combined $122M — up 17% from $105M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of FPRX and 9 opened new positions — a net loss of 9 holders — while 37 trimmed existing stakes and 34 added.

The largest buyer was BVF Inc, adding an estimated $15.9M. The largest seller was Wellington Management Group, cutting an estimated $4.62M.

  • 94 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q4 2019, down from 103 in Q3 2019.
  • Funds reported $122M of Five Prime Therapeutics, Inc. stock for Q4 2019, up 17% quarter-over-quarter.
  • 9 funds opened new Five Prime Therapeutics, Inc. positions in Q4 2019 and 18 closed out, a net change of -9 holders.
  • The largest Five Prime Therapeutics, Inc. buyer in Q4 2019 was BVF Inc, an estimated $15.9M added.
  • The largest Five Prime Therapeutics, Inc. seller in Q4 2019 was Wellington Management Group, an estimated $4.62M sold.

Based on aggregated 13F filings for Q4 2019.